What is the recommended dose and titration schedule for rosuvastatin?

Rosuvastatin Dosing Recommendations

For most adults with established atherosclerotic cardiovascular disease (ASCVD), initiate rosuvastatin at 20 mg once daily as high-intensity therapy to achieve ≥50% LDL-C reduction and maximize cardiovascular event reduction. 1, 2

Standard Dosing by Clinical Indication

Secondary Prevention (Established ASCVD)

Adults ≤75 years:

• Start rosuvastatin 20 mg once daily as the standard high-intensity dose for patients with prior myocardial infarction, acute coronary syndrome, stroke, TIA, or peripheral arterial disease 1, 2
• If baseline LDL-C is markedly elevated (>190 mg/dL), consider rosuvastatin 20 mg + ezetimibe 10 mg as initial combination therapy rather than sequential titration 1, 3
• Target LDL-C <55 mg/dL (1.4 mmol/L) with ≥50% reduction from baseline 1
• Reassess lipids at 4–6 weeks; if LDL-C remains >55 mg/dL, add ezetimibe 10 mg or increase to rosuvastatin 40 mg 1, 4

Adults >75 years:

• Consider moderate-intensity therapy (rosuvastatin 5–10 mg daily) as high-intensity therapy has not demonstrated additional ASCVD event reduction in this age group 1, 2

Primary Prevention

LDL-C ≥190 mg/dL (severe hypercholesterolemia):

• Initiate rosuvastatin 20–40 mg once daily regardless of other risk factors 1, 2
• If LDL-C remains ≥100 mg/dL after 4–8 weeks on maximally tolerated statin, add ezetimibe 10 mg 1, 3

10-year ASCVD risk ≥7.5% (ages 40–75):

• Start rosuvastatin 10 mg once daily (moderate-intensity) for most patients 1, 2
• For patients with multiple risk factors or diabetes, consider rosuvastatin 20 mg (high-intensity) 1

Diabetes mellitus (ages 40–75):

• Rosuvastatin 10–20 mg once daily depending on additional risk factors 1

Dose Titration Algorithm

1. Baseline: Obtain fasting lipid panel, creatine kinase (CK), ALT, AST; screen for active liver disease, pregnancy, drug interactions 2

2. Week 4–8: Repeat fasting lipids, ALT, AST 2, 4

   • If LDL-C goal not met and labs acceptable: increase dose by one increment (5→10→20→40 mg) 2, 5
   • Each dose doubling yields an additional ≈6% LDL-C reduction 2, 5
   • Withhold if transaminases ≥3× upper limit of normal 2

3. Month 3–4: Repeat lipid panel after any dose adjustment 2

4. Ongoing: Monitor lipids and liver enzymes every 3–4 months during first year, then every 6 months 2

Expected LDL-C Reductions by Dose

• Rosuvastatin 5 mg: 39–42% reduction (moderate-intensity) 1, 6, 7
• Rosuvastatin 10 mg: 46–47% reduction (moderate-intensity) 1, 2, 6
• Rosuvastatin 20 mg: 52–55% reduction (high-intensity) 1, 2
• Rosuvastatin 40 mg: 55–63% reduction (high-intensity) 1, 2

Special Population Adjustments

Asian Patients

• Start at 5 mg once daily due to significantly higher plasma concentrations (approximately 2-fold increase) 4
• Do not exceed 20 mg daily without careful risk-benefit assessment 4

Severe Renal Impairment (CrCl <30 mL/min, not on dialysis)

• Start at 5 mg once daily 1, 4
• Do not exceed 10 mg once daily 1, 4
• No adjustment needed for mild-to-moderate renal impairment 4

Patients with Diabetes or Metabolic Syndrome

• For high-risk patients with diabetes/metabolic syndrome, consider rosuvastatin 20 mg + ezetimibe 10 mg upfront to reduce LDL-C while minimizing new-onset diabetes risk compared to higher statin doses alone 1

Critical Drug Interactions Requiring Dose Limits

Concomitant Drug	Maximum Rosuvastatin Dose
Cyclosporine	5 mg once daily (7-fold increase in exposure) [4]
Gemfibrozil	Avoid; if necessary, 5 mg once daily and do not exceed 10 mg [4]
Atazanavir/ritonavir, lopinavir/ritonavir	10 mg once daily [4]
Teriflunomide, enasidenib, capmatinib, regorafenib	10 mg once daily [4]
Fostamatinib, febuxostat	20 mg once daily [4]
Resmetirom (for MASH/NASH)	20 mg once daily [2]

Administration Details

• Take once daily at any time of day, with or without food 4
• Swallow tablets whole 4
• If taking aluminum/magnesium hydroxide antacids, administer rosuvastatin at least 2 hours before the antacid 4
• If a dose is missed, do not double the next dose—simply resume with the next scheduled dose 4

Combination Therapy with Ezetimibe

When to add ezetimibe:

• LDL-C remains above goal after 4–6 weeks on maximally tolerated statin 1, 3
• Baseline LDL-C is very high (>190 mg/dL) in high-risk patients 1, 3
• Patient cannot tolerate higher statin doses due to muscle symptoms 3

Dosing:

• Ezetimibe 10 mg once daily added to current rosuvastatin dose 3
• Rosuvastatin 10 mg + ezetimibe 10 mg produces greater LDL-C lowering than rosuvastatin 20 mg alone with fewer adverse events 3
• Combination achieves >50% LDL-C reduction across all dose combinations 3

Monitoring:

• Repeat lipid panel 4–6 weeks after adding ezetimibe 3
• If LDL-C still >55 mg/dL (post-ACS) or >70 mg/dL (other high-risk), add PCSK9 inhibitor 1, 3

Common Pitfalls to Avoid

1. Do NOT use moderate-intensity doses (5–10 mg) for secondary prevention in patients ≤75 years—high-intensity therapy (20–40 mg) is required 2

2. Do NOT prescribe rosuvastatin three times weekly—once-daily dosing is required to achieve guideline-recommended LDL-C reductions and cardiovascular protection 2

3. Do NOT automatically start all patients at 10 mg—Asian patients and those with severe renal impairment require the lower 5 mg starting dose to avoid excessive drug exposure and myopathy risk 2, 4

4. Do NOT use ezetimibe monotherapy—when statin therapy is possible, combination therapy provides superior LDL-C reduction and proven cardiovascular event reduction 3

5. Do NOT delay adding ezetimibe—if LDL-C is not at goal after 4–6 weeks on statin, add ezetimibe immediately rather than waiting months 1

Safety Monitoring

• If muscle symptoms develop: Stop rosuvastatin immediately and obtain CK level; CK ≥10× upper limit of normal warrants discontinuation 2
• Myopathy incidence: <0.1% at recommended doses (5–40 mg daily) 2
• New-onset diabetes risk: Slight increase, particularly in patients with metabolic syndrome features 2
• Proteinuria risk: Higher with 40 mg versus 20 mg daily (monitor in patients with renal disease) 5